ArticleHaematologica2026
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of exhausted CD8Translational cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Various drug classes target B-cell maturation antigen (BCMA) including chimeric antigen receptor T-cell (CAR T) therapies, bispecific antibodies (bsAb), and antibody-drug conjugates (ADC). Outcomes with CAR T and bsAb therapies in multiple myeloma (MM) have been affected by T-cell exhaustion, and abrogated expression/mutation of the BCMA target has been observed with anti-BCMA therapies. Optimal anti-BCMA sequencing strategies are needed to improve long-term clinical outcomes. We used data from multiple clinical studies of the ADC belantamab mafodotin (as monotherapy and combination regimens) to explore its impact on BCMA levels and binding (using electrochemiluminescence methodology) and T-cell/ natural killer (NK) cell fitness (including cell counts, expression of functional markers), to determine whether belantamab mafodotin could be sequenced ahead of other BCMA-targeting therapies for MM. Levels of free soluble BCMA (sBCMA), measured at the best-confirmed response (BCR) and at progression, dropped at BCR but returned to near baseline at time of disease progression. There was no apparent impact on the binding epitope of BCMA, as indicated by the retention of belantamab mafodotin binding to sBCMA. No significant changes in cell counts or expression of T-cell exhaustion markers (PD-1, TIGIT, TIM-3 [except NK cells], or CTLA-4) and co-stimulatory markers (ICOS [except CD4+ T cells], OX40, 4-1BB) were observed at relevant time points (up to 4 or 21+ months depending on the marker). No negative impact was observed on expression of proliferation (Ki67) and antitumor activity (granzyme B, CD107a) markers. Pending confirmatory studies, our results indicate potential for utilizing belantamab mafodotin ahead of other anti-BCMA therapies in MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.